Applied BioCode (6598) — Cash Flow-to-Debt Ratio
Applied BioCode (6598) has a Cash Flow-to-Debt Ratio of -0.06x as of September 2025, meaning its operating cash flow of NT$-19.88 Million could theoretically repay 0% of its total liabilities (NT$343.23 Million) in one year. See how financially flexible is Applied BioCode to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Applied BioCode Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Applied BioCode across 12 annual periods. For the full cash flow conversion analysis, see Applied BioCode cash conversion from operations.
Annual Cash Flow-to-Debt Ratio for Applied BioCode (2013–2024)
Year-by-year debt coverage analysis for Applied BioCode. Check Applied BioCode earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.62x | NT$-207.74 Million | NT$336.07 Million | ▼ -0.1% |
| 2023 | -0.62x | NT$-205.09 Million | NT$332.22 Million | ▼ -267.7% |
| 2022 | 0.37x | NT$145.87 Million | NT$396.38 Million | ▲ +128.1% |
| 2021 | -1.31x | NT$-151.77 Million | NT$116.01 Million | ▼ -25.0% |
| 2020 | -1.05x | NT$-146.74 Million | NT$140.23 Million | ▲ +37.2% |
| 2019 | -1.67x | NT$-313.84 Million | NT$188.36 Million | ▲ +52.7% |
| 2018 | -3.52x | NT$-286.71 Million | NT$81.35 Million | ▲ +15.1% |
| 2017 | -4.15x | NT$-250.36 Million | NT$60.30 Million | ▲ +52.7% |
| 2016 | -8.77x | NT$-448.96 Million | NT$51.17 Million | ▼ -70.6% |
| 2015 | -5.14x | NT$-209.24 Million | NT$40.67 Million | ▼ -55.6% |
| 2014 | -3.31x | NT$-128.80 Million | NT$38.97 Million | ▲ +15.0% |
| 2013 | -3.89x | NT$-91.93 Million | NT$23.63 Million | — |